Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overacti...( - Innovative pipeline products highl...),Health

- Innovative pipeline products highlight Watson's commitment to urology -

Embargoed Until 2:10 PM EDT

ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical data on two Phase 3 products at the American Urological Association's annual meeting. The abstracts include a cardiac safety trial involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of oxybutynin chloride topical gel (OTG), an investigational product for overactive bladder.

"Watson is committed to helping urologists offer their patients the highest standard of care through providing novel treatments that continually address areas of urology with limited therapeutic options," said Edward Heimers, Jr., Executive Vice President and President of Watson's Brand Division. "We are extremely encouraged by the results demonstrated in these two trials, as they support the safety of silodosin and the potential efficacy of OTG as well as offer important patient benefits. A marketing application for silodosin has been filed with the FDA, and one for OTG will be filed. Both products represent potentially important additions to the expanding Watson urology franchise."

In the first trial (abstract #2037), investigators conducted a double-blind, randomized, parallel-group trial to assess whether or not silodosin -- an investigational alpha blocker -- would prolong the QT interval on an electrocardiogram (ECG). QT is a measure of the heart's electrical activity. A prolongation of the QTc (corrected for heart rate) interval favors the develo
'/>"/>